Bioretec Oy

Bioretec Oy Net Margin

The Net Profit Margin of Bioretec Oy (BRETEC.HE) as of Nov 5, 2026 is -269.27 %. In the previous year, Net Profit Margin was -101.54 % — a change of 165.18% (lower).

Net Margin

-269.27 %

YoY

165.18%

Last updated:

Net Profit Margin of Bioretec Oy is 2025 -269.27 % . Net Profit Margin of Bioretec Oy was 2024 -101.54 % . It decreases by 165.18% lower compared to the previous year.

Bioretec Oy's net margin stands at -269.3%, up from -300.4% several years earlier.

The Bioretec Oy Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-129.59 EUR
Jan 1, 2019
-99.34 EUR
Jan 1, 2020
-150.66 EUR
Jan 1, 2021
-300.39 EUR
Jan 1, 2022
-82.13 EUR
Jan 1, 2023
-96.99 EUR
Jan 1, 2024
-101.54 EUR
Jan 1, 2025
-269.27 EUR
The Bioretec Oy Net Margin history
YEARNet MarginYoY
-269.27 %+165.18%
-101.54 %+4.69%
-96.99 %+18.09%
-82.13 %-72.66%
-300.39 %+99.39%
-150.66 %+51.66%
-99.34 %-23.35%
-129.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioretec Oy Stock analysis

What does Bioretec Oy do? Bioretec Oy develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics, operating as a developer, manufacturer, and commercializer of innovative bioresorbable orthopedic implants and implant materials. The company's Activa product portfolio includes bioabsorbable biopolymer products available in the market for pediatric, trauma, and sports surgery applications. Bioretec Oy has a Germany-based subsidiary, BRI.Tech GmbH, and its products are used globally across various medical specialties. The company generates revenue through the sale of its Activa product portfolio, targeting healthcare providers and medical institutions worldwide. The Activa products are designed for bone and soft tissue injury treatments, serving segments in pediatrics, trauma surgery, and sports medicine. Bioretec Oy's global distribution network enables the commercialization of its implants in international markets. Bioretec Oy's business model focuses on the development, manufacturing, and commercialization of bioresorbable orthopedic solutions. The company's products are marketed under the Activa brand, catering to medical professionals in specialized surgical fields. The Germany-based subsidiary BRI.Tech GmbH supports the company's operations in the European market. Bioretec Oy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioretec Oy stock

Net Profit Margin of Bioretec Oy is -269.27 % in 2025.

Net Profit Margin of Bioretec Oy changed from -101.54 % to -269.27 %, representing a 165.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Bioretec Oy since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Bioretec Oy with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Bioretec Oy

All Key Metrics — Bioretec Oy